

12 March 2014

## Global Fund Country Allocations: 2014-2016

In 2014, the Global Fund is implementing a new funding model. As partners in the response to HIV, tuberculosis and malaria, we expect to reach more people affected by the diseases and increase overall impact.

With a more strategic approach based on national plans, the new funding model will support countries in planning how to control these epidemics and to provide care and treatment to people affected by them, including strengthening of health systems. The new funding model relies on strong country dialogue to bring partners together to best decide how to maximize impact, and to look at how all available resources can serve a country's objectives.

In most countries, there will be a funding gap between ultimate goals and available resources. Everyone needs to be ambitious to defeat these diseases. By prioritizing and focusing on maximum impact, we may be able to achieve more than seems possible today.

### Here is a list of Country Allocations for 2014-2016

Country	Disease	Allocation (US\$ million)	Country	Disease	Allocation (US\$ million)
Afghanistan*	HIV	14.1	Madagascar	HIV	17.2
Afghanistan*	TB	22.4	Madagascar	TB	10.6
Afghanistan*	Malaria	31.3	Madagascar	Malaria	84.6
Albania	HIV	5.1	Malawi*	HIV	474.6
Albania	TB	0.9	Malawi*	TB	13.0
Algeria	HIV	6.5	Malawi*	Malaria	86.8
Angola	HIV	23.3	Malaysia	HIV	6.8
Angola	TB	8.8	Mali	HIV	110.6
Angola	Malaria	60.2	Mali	TB	13.9
Armenia*	HIV	9.8	Mali	Malaria	94.2
Armenia*	TB	12.6	Mauritania	HIV	11.5
Azerbaijan	HIV	19.8	Mauritania	TB	4.8
Azerbaijan	TB	18.0	Mauritania	Malaria	15.6
Bangladesh	HIV	34.5	Mauritius	HIV	5.1
Bangladesh	TB	90.4	Mongolia*	HIV	5.9
Bangladesh	Malaria	30.4	Mongolia*	TB	10.9
Belarus	HIV	20.6	Morocco	HIV	24.6
Belarus	TB	17.4	Morocco	TB	12.8
Belize	HIV	3.2	Mozambique*	HIV	252.6
Belize	TB	1.3	Mozambique*	TB	52.8
Benin*	HIV	86.7	Mozambique*	Malaria	144.8
Benin*	TB	14.4	Myanmar	HIV	117.7

Country	Disease	Allocation (US\$ million)	Country	Disease	Allocation (US\$ million)
Benin*	Malaria	62.8	Multi-country Caribbean <sup>1</sup>	TB-HIV	5.3
Bhutan	HIV	2.4	Multi-country Western Pacific <sup>2</sup>	TB-HIV	21.2
Bhutan	TB	2.6	Multi-country Western Pacific <sup>3</sup>	Malaria	9.7
Bhutan	Malaria	2.6	Myanmar	TB	81.8
Bolivia	HIV	15.6	Myanmar	Malaria	57.5
Bolivia	TB	12.8	Namibia	HIV	87.7
Bolivia	Malaria	12.8	Namibia	TB	18.1
Botswana	HIV	18.1	Namibia	Malaria	5.5
Botswana	TB	5.5	Nepal	HIV	38.2
Botswana	Malaria	5.1	Nepal	TB	23.7
Bulgaria	HIV	9.2	Nicaragua	Malaria	14.7
Bulgaria	TB	10.3	Nicaragua	HIV	17.4
Burkina Faso	HIV	77.1	Nicaragua	TB	11.7
Burkina Faso	TB	11.9	Nicaragua	Malaria	11.7
Burkina Faso	Malaria	115.6	Niger*	HIV	24.3
Burundi	HIV	82.3	Niger*	TB	51.6
Burundi	TB	9.5	Niger*	Malaria	88.1
Burundi	Malaria	36.3	Nigeria	HIV	477.4
Cambodia*	HIV	80.8	Nigeria	TB	160.5
Cambodia*	TB	15.9	Nigeria	Malaria	499.5
Cambodia*	Malaria	52.1	Pakistan	HIV	28.5
Cameroon	HIV	155.2	Pakistan	TB	174.5
Cameroon	TB	15.0	Pakistan	Malaria	52.0
Cameroon	Malaria	118.1	Panama	HIV	5.7
Cape Verde	HIV	5.0	Panama	TB	2.2
Cape Verde	Malaria	1.3	Papua New Guinea	HIV	25.2
Central African Republic	HIV	36.1	Papua New Guinea	TB	13.7
Central African Republic	TB	12.0	Papua New Guinea	Malaria	44.3
Central African Republic	Malaria	32.1	Paraguay*	HIV	12.5
Chad	HIV	64.1	Paraguay*	TB	8.4

<sup>1</sup> The multi-country Caribbean allocation for tuberculosis and HIV includes the following eligible countries: Dominica, Grenada, St. Lucia and St. Vincent and the Grenadines.

<sup>2</sup> The multi-country Western Pacific allocation for tuberculosis and HIV includes the following eligible countries: Kiribati, Marshall Islands, Micronesia, Samoa, Solomon Islands, Tonga, Tuvalu and Vanuatu.

<sup>3</sup> The multi-country Western Pacific allocation for malaria includes the following eligible countries: Solomon Islands and Vanuatu.

\* Country has existing funding in a health systems strengthening grant. This funding has been included proportionally in each eligible component for the purposes of this document. Allocation letters to countries show this funding separately.

\* Country has existing funding in a health systems strengthening grant. This funding has been included proportionally in each eligible component for the purposes of this document. Allocation letters to countries show this funding separately.

Country	Disease	Allocation (US\$ million)	Country	Disease	Allocation (US\$ million)
Chad	TB	8.8	Paraguay*	Malaria	5.4
Chad	Malaria	97.9	Peru	HIV	12.8
Colombia	HIV	19.4	Peru	TB	15.0
Comoros	HIV	3.3	Philippines	HIV	14.4
Comoros	TB	2.5	Philippines	TB	71.7
Comoros	Malaria	13.3	Philippines	Malaria	22.2
Congo	HIV	27.5	Republic of Moldova	HIV	19.6
Congo	TB	3.9	Republic of Moldova	TB	19.9
Costa Rica	HIV	4.9	Romania	TB	12.8
Côte d'Ivoire	HIV	112.9	Russian Federation	HIV	15.7
Côte d'Ivoire	TB	28.5	Rwanda	HIV	294.6
Côte d'Ivoire	Malaria	118.7	Rwanda	TB	36.5
Cuba	HIV	21.8	Rwanda	Malaria	64.8
Democratic People's Republic of Korea	TB	43.0	Sao Tome & Principe	HIV	1.3
Democratic People's Republic of Korea	Malaria	15.9	Sao Tome & Principe	TB	1.4
Democratic Republic of the Congo*	HIV	177.9	Sao Tome & Principe	Malaria	10.9
Democratic Republic of the Congo*	TB	86.8	Senegal	HIV	47.8
Democratic Republic of the Congo*	Malaria	436.8	Senegal	TB	13.5
Djibouti	HIV	6.0	Senegal	Malaria	62.4
Djibouti	TB	6.4	Sierra Leone	HIV	48.2
Djibouti	Malaria	7.8	Sierra Leone	TB	10.8
Dominican Republic	HIV	37.0	Sierra Leone	Malaria	67.4
Dominican Republic	TB	12.8	Somalia	HIV	28.8
Ecuador	HIV	16.3	Somalia	TB	33.5
Egypt	HIV	7.0	Somalia	Malaria	49.9
Egypt	TB	11.1	South Africa	HIV	386.7
El Salvador	HIV	23.7	South Africa	TB	78.1
El Salvador	TB	10.3	Sri Lanka*	HIV	16.0
El Salvador	Malaria	3.9	Sri Lanka*	TB	12.2

\* Country has existing funding in a health systems strengthening grant. This funding has been included proportionally in each eligible component for the purposes of this document. Allocation letters to countries show this funding separately.

\*\* Only eligible for transition funding

Country	Disease	Allocation (US\$ million)	Country	Disease	Allocation (US\$ million)
Eritrea	HIV	39.2	Sri Lanka*	Malaria	17.3
Eritrea	TB	9.5	Sudan	HIV	38.0
Eritrea	Malaria	36.1	Sudan	TB	28.2
Ethiopia*	HIV	379.8	Sudan	Malaria	98.6
Ethiopia*	TB	60.4	Sudan South*	HIV	47.0
Ethiopia*	Malaria	150.9	Sudan South*	TB	15.6
Fiji**	TB	5.4	Sudan South*	Malaria	73.2
Gabon	HIV	0.2	Suriname	HIV	2.6
Gabon	TB	5.1	Suriname	TB	2.6
Gambia	HIV	20.1	Suriname	Malaria	2.6
Gambia	TB	6.8	Swaziland*	HIV	48.5
Gambia	Malaria	26.2	Swaziland*	TB	26.7
Georgia	HIV	33.9	Swaziland*	Malaria	5.2
Georgia	TB	22.6	Syrian Arab Republic	HIV	5.5
Ghana	HIV	121.2	Syrian Arab Republic	TB	7.2
Ghana	TB	27.7	Tajikistan	HIV	24.7
Ghana	Malaria	125.1	Tajikistan	TB	27.5
Guatemala	HIV	44.8	Tajikistan	Malaria	1.3
Guatemala	TB	9.9	Tanzania, United Republic (Mainland)*	HIV	402.5
Guatemala	Malaria	19.4	Tanzania, United Republic (Mainland)*	TB	27.7
Guinea	HIV	45.0	Tanzania, United Republic (Mainland)*	Malaria	202.4
Guinea	TB	12.0	Tanzania, United Republic (Zanzibar)	HIV	5.2
Guinea	Malaria	73.0	Tanzania, United Republic (Zanzibar)	TB	5.2
Guinea-Bissau	HIV	18.2	Tanzania, United Republic (Zanzibar)	Malaria	5.0
Guinea-Bissau	TB	7.0	Thailand	HIV	50.6
Guinea-Bissau	Malaria	27.4	Thailand	TB	22.7
Guyana	HIV	13.6	Thailand	Malaria	35.7
Guyana	TB	2.4	Timor-Leste	HIV	7.6
Guyana	Malaria	2.6	Timor-Leste	TB	5.1
Haiti	HIV	78.9	Timor-Leste	Malaria	16.0
Haiti	TB	15.6	Togo	HIV	52.3

\* Country has existing funding in a health systems strengthening grant. This funding has been included proportionally in each eligible component for the purposes of this document. Allocation letters to countries show this funding separately.

\*\* Only eligible for transition funding

Country	Disease	Allocation (US\$ million)	Country	Disease	Allocation (US\$ million)
Haiti	Malaria	25.6	Togo	TB	8.7
Honduras	HIV	20.4	Togo	Malaria	52.2
Honduras	TB	10.3	Tunisia	HIV	12.3
Honduras	Malaria	10.3	Turkmenistan	TB	9.8
India	HIV	562.3	Uganda*	HIV	251.7
India	TB	232.9	Uganda*	TB	23.9
India	Malaria	54.8	Uganda*	Malaria	145.4
Indonesia*	HIV	116.1	Ukraine	HIV	137.3
Indonesia*	TB	107.8	Ukraine	TB	47.3
Indonesia*	Malaria	78.4	Uzbekistan	HIV	27.7
Iran (Islamic Republic of)	HIV	20.2	Uzbekistan	TB	35.4
Iraq**	TB	10.7	Uzbekistan	Malaria	1.4
Jamaica	HIV	19.1	Viet Nam*	HIV	93.0
Kazakhstan	TB	43.5	Viet Nam*	TB	47.1
Kenya	HIV	337.3	Viet Nam*	Malaria	18.3
Kenya	TB	45.0	West Bank and Gaza (Palestine)	HIV	4.8
Kenya	Malaria	113.1	West Bank and Gaza (Palestine)	TB	1.8
Kosovo	HIV	4.9	Yemen	HIV	11.5
Kosovo	TB	5.1	Yemen	TB	11.5
Kyrgyzstan	HIV	29.1	Yemen	Malaria	16.8
Kyrgyzstan	TB	14.7	Zambia	HIV	228.9
Kyrgyzstan	Malaria	0.5	Zambia	TB	14.5
Lao People's Democratic Republic	HIV	13.8	Zambia	Malaria	53.3
Lao People's Democratic Republic	TB	10.1	Zimbabwe*	HIV	398.9
Lao People's Democratic Republic	Malaria	14.5	Zimbabwe*	TB	38.6
Lesotho	HIV	86.2	Zimbabwe*	Malaria	40.2
Lesotho	TB	7.0			
Liberia	HIV	45.2			
Liberia	TB	9.6			
Liberia	Malaria	47.1			

\* Country has existing funding in a health systems strengthening grant. This funding has been included proportionally in each eligible component for the purposes of this document. Allocation letters to countries show this funding separately.